Clinical Report: One-time Base Editing Lowers Cholesterol in Phase 1 Study
Overview
VERVE-102, an investigational in vivo adenine base-editing therapy, demonstrated significant reductions in PCSK9 and LDL-C levels in a phase 1 study. No dose-limiting toxicities were reported among participants.
Background
Cholesterol management is critical in preventing cardiovascular diseases, particularly in patients with conditions like heterozygous familial hypercholesterolemia. Traditional therapies often require ongoing treatment.
Data Highlights
| Parameter | Reduction |
|---|---|
| PCSK9 | Up to 88% |
| LDL-C | Up to 62% |
Key Findings
- VERVE-102 is designed to inactivate PCSK9 in the liver.
- The therapy was administered as a one-time treatment using mRNA in a lipid nanoparticle.
- In the study, 35 participants received VERVE-102 across six dose cohorts.
- No dose-limiting toxicities were reported; mild-to-moderate infusion reactions and transient liver enzyme elevations were observed.
- Effects of the therapy appeared durable through follow-up of at least one year in 15 participants.
Clinical Implications
The findings suggest that VERVE-102 could offer a new therapeutic option for patients with elevated cholesterol levels, potentially reducing the need for lifelong medication. Ongoing monitoring of long-term effects and safety will be essential as this therapy progresses.
Conclusion
VERVE-102 demonstrates promising results in lowering cholesterol through a single gene-editing intervention, warranting further investigation in larger trials.
Related Resources & Content
- Verve Therapeutics, New England Journal of Medicine, 2026 -- In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
- the medicine maker — This Week’s CGT News: New FDA Genome Editing Guidance
- the medicine maker — This Week’s CGT News: CRISPR Hits Phase 3 Milestone
- Associated Press Health — Could gene editing offer the one-time fix for artery-clogging cholesterol?
- Frontiers in Cardiovascular Medicine — Editorial: New drugs in lipid lowering therapy
- Could gene editing offer the one-time fix for artery-clogging cholesterol?
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | New England Journal of Medicine
- In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia | New England Journal of Medicine
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
